Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: Implications in gene therapy

Virology

Volumn 272, Issue 1, 2000, Pages 159-167

  Moffatt, Stanley ^a   Hays, John ^b   Hogenesch, Harm ^a   Mittal, Suresh K ^a  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Bovine adenovirus; Gene therapy; Human adenovirus; Non human adenovirus; Porcine adenovirus

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

ADENOVIRIDAE; ANIMALIA; BACTERIA (MICROORGANISMS); BOVINAE; BOVINE ADENOVIRUS; BOVINE ADENOVIRUS 3; CYTOMEGALOVIRUS; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS TYPE 3; HUMAN ADENOVIRUS TYPE 5; MOUSE CYTOMEGALOVIRUS 1; MURINAE; ORYCTOLAGUS CUNICULUS; PORCINE ADENOVIRUS; PORCINE ADENOVIRUS 3; SUIDAE;

EID: 0034691085     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0350     Document Type: Article

References (46)

1. Adam E., Nasz I., Lengyel A. Antigenic homogeneity among the adenovirus hexon types of subgenus C. Arch. Virol. 140:1995;1297-1301.
2. Addison C. L., Hitt M., Kunsken D., Graham F. L. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J. Gen. Virol. 78:1997;1653-1661.
3. Aggarwal N., HogenEsch H., Guo P., North A., Suckow M., Mittal S. Biodegradable alginate microspheres as a delivery system for naked DNA. Can. J. Vet. Sci. 63:1999;148-152.
4. Barr D., Tubb J., Scaria A., Lieber A., Wilson C., Perkins J., Kay M. A. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 2:1995;151-155.
5. Berkner K. L. Development of adenovirus vectors for the expression of heterologous genes. BioTechniques. 6:1988;616-629.
6. Collins P. L., Prince G. A., Camargo E., Purcell R. H., Chanock R. M., Murphy B. R. Evaluation of the protective efficacy of recombinant vaccinia viruses and adenoviruses that express respiratory syncytial virus glycoproteins. Brown R. M., Chanock H., Ginsberg H., Lerner R. A. Vaccines: Modern Approaches to New Vaccines Including Prevention of AIDS. 1990;79-84 Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
7. Crystal R. G. Transfer of genes to humans: Early lessons and obstacles to success. Science. 270:1995;404-410.
8. Dai Y., Schwarz E. M., Gu D., Zhang W-W., Sarvetnick M., Verma I. M. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long term expression. Proc. Natl. Acad. Sci. USA. 92:1995;1401-1405.
9. Dong J. Y., Wang D. H., Vanginkel F. W., Pascual D. W., Frizzell R. A. Systemic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Hum. Gene Ther. 7:1996;319-331.
10. Engelhardt J. F., Ye X., Doranz B., Wilson J. M. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA. 91:1994;6196-6200.
11. Fisher K. J., Choi H., Burda J., Chen S-J., Wilson J. M. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology. 217:1996;11-22.
12. Graham F. L. Adenoviruses as expression vectors and recombinant vaccines. Trends Biotechnol. 8:1990;85-87.
13. Graham F. L., Prevec L. Adenovirus expression vectors and recombinant vaccines. Ellis R. W. Vaccines: New Approaches to Immunological Problems. 1992;363-390 Butterworth-Heineman, Boston.
14. Guibinga G.-H., Lochmuller H., Massie B., Nalbantoglu J., Karpati G., Petrof B. J. Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles. J. Virol. 72:1998;4601-4609.
15. Hierholzer J. C. Adenovirus in the immunocompromised host. Clin. Microbiol. Rev. 5:1992;262-274.
16. Hoffman C., Loser P., Cichon G., Arnold W., Both G. W., Strauss M. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J. Virol. 73:1999;6930-6936.
17. Ilan Y., Sauter B., Roy Chowdhury N., Reddy B. V. N., Thummala N. R., Droguett G., Davidson A., Ott M., Horwitz M. S., Roy Chowdhury J. Oral tolerization to adenoviral proteins permits repeated adenovirus mediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology. 27:1998;1368-1376.
18. Kafri T., Morgan D., Krahl T., Sarvetnick N., Sherman L., Verma I. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: Implications for gene therapy. Proc. Natl. Acad. Sci. USA. 95:1998;11377-11382.
19. Kagami H., Atkinson J. C., Michalek S. M., Handelman B., Yu S., Baum B. J., O'Connell B. Repetitive adenovirus administration to the parotid gland: Role of immunological barriers and induction of oral tolerance. Hum. Gene Ther. 9:1998;305-313.
20. Kaier B., Wigand R. Antigenic homogeneity of adenovirus serotypes 1,2,5 and 6. J. Med. Virol. 18:1986;283-287.
21. Kanesaki T., Murphy B. R., Collins P. L., Ogra P. L. Effectiveness of enteric immunization in the development of secretory immunoglobin A response and the outcome of infection with respiratory syncytial virus. J. Virol. 65:1991;557-663.
22. Kass-Eisler A., Leinwand L., Gall J., Bloom B., Falck-Pederson E. Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther. 3:1996;154-162.
23. Kay M. A., Holterman A. X., Meuse L., Gown A., Ochs O. D., Linsley P. S., Wilson C. B. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat. Genet. 11:1995;191-197.
24. Klonjkowski B., Gilardi-Hebenstreit P., Hadchouel J., Randrianarison V., Boutin S., Yeh P., Perricaudet M., Kremer E. J. A recombinant E1-deleted canine adenoviral vector capable of transduction and expression of a transgene in human-derived cells and in vitro. Hum. Gene Ther. 8:1997;2103-2115.
25. Kochanek S., Clemens P., Mitani K., Chen H., Chan S., Caskey T. A new adenoviral vector: Replacement of viral coding sequences with 28 kb DNA independently expressing both full-length dystrophin and β-galactosidase. Proc. Natl. Acad. Sci. USA. 93:1996;5731-5736.
26. Kozarsky K. F., McKinley D. R., Austin L. L., Raper S. E., Stratford, Perricaudet L. D., Wilson J. M. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J. Biol. Chem. 269:1994;13695-13702.
27. Mack C. A., Wen-Ru S., Carpenter H., Wickham T. J., Kovesdi I., Harvey B-G., Magovern C. J., Isom O. W., Rosengart T., Falck-Pedersen E., Hackett N. R., Crystal R. J., Mastrangeli A. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum. Gene Ther. 8:1997;99-109.
28. McLane S. J., Chirmule N., Burke C. V., Raper S. E. Characterization of the immune response after local delivery of recombinant adenovirus in murine pancreas and successful strategies for readministration. Hum. Gene Ther. 8:1997;2207-2216.
29. Meitin C. A., Bender B. S., Small P. A. Enteric immunization of mice against influenza with recombinant vaccinia. Proc. Natl. Acad. Sci. USA. 91:1994;11187-11191.
30. Mittal S. K., McDermott M. R., Johnson D. C., Prevec L., Graham F. L. Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter. Virus Res. 28:1993;67-90.
31. Mittal S. K., McDermott M. R., Johnson D. C., Prevec L., Zamb T., Babiuk L. A., Graham F. L. Adenovirus-based expression vectors for recombinant vaccines. Talwar G. P. Recombinant and Synthetic Vaccines. 1994;362-366 Springer-Verlag, New York.
32. Mittal S. K., Prevec L., Graham F. L., Babiuk L. Development of bovine adenovirus type 3-based expression vector. J. Gen. Virol. 76:1995a;93-102.
33. Mittal S. K., Middleton D. M., Tikoo S. K., Babiuk L. A. Pathogenesis and immunogenicity of bovine adenovirus type 3 in cotton rats (Sigmodon hispidus). Virology. 213:1995b;131-139.
34. Morsy M. A., Gu M., Motzel S., Zhao J., Lin J., Su J. Q., Allen H., Franlin L., Parks J. R., Kochanek S., Bett A. J., Caskey C. T. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin gene. Proc. Natl. Acad. Sci. USA. 14:1998;7866-7871.
35. Papp Z., Middleton D. M., Mittal S. K., Babiuk L. A., Baca-Estrada M. E. Mucosal immunization with recombinant adenoviruses: Induction of immunity and protection of cotton rats against respiratory bovine herpesvirus type 1 infection. J. Gen. Virol. 78:1997;2933-2943.
36. Rasmussen U. B., Benchaibi M., Meyer V., Schlesinger Y., Schughart K. Novel human gene transfer vectors: Evaluation of wild-type and recombinant animal adenoviruses in human-derived cells. Hum. Gene Ther. 16:1999;2587-2599.
37. Reddy P. S., Neeraja I., Bang-Hun H., Tikoo S. K. Development of porcine adenovirus-3 as an expression vector. J. Gen. Virol. 80:1999;563-570.
38. Roy S., Shirley P. S., McClelland A., Kaleko M. Circumvention of immunity to the adenovirus major coat protein hexon. J. Virol. 72:1998;6875-6879.
39. Setoguchi Y., Jaffe H. A., Chu C. S., Crystal R. G. Intraperitoneal in vivo gene therapy to deliver alpha 1-antitrypsin to the systemic circulation. Am. J. Respir. Cell Mol. Biol. 10:1994;369-377.
40. Shenk T. Adenoviridae: The viruses and their replication. Fields B. N., Knipe D. M., Howley P. M. Fields Virology. 1996;2111 Lippincott-Raven, Philadelphia.
41. Smith T. A., Mehaffey M. G., Kayda D. B., Saunders J. M., Yei S., Trapnell B. C., McClelland A., Kaleko M. Adenovirus-mediated therapeutic plasma levels of human plasma IX in mice. Nat. Genet. 5:1993;397-402.
42. Smith T. A., White B. D., Gardner J. M., Kaleko M., McClelland A. Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther. 3:1996;496-502.
43. Walter J., You Q. M., Hagstrom J. N., Sands M., High K. A. Successful expression of human factor IX following repeat administration of an adenoviral vector in mice. Proc. Natl. Acad. Sci. USA. 93:1996;3056-3061.
44. Yang Y., Nunes F. A., Berencsi K., Furth E. E., Gonczol E., Wilson J. M. Cellular immunity to viral antigens limits E1-deleted adenovirus for gene therapy. Proc. Natl. Acad. Sci. USA. 91:1994;4407-4411.
45. Yang Y., Li Q., Ertl H. C., Wilson J. M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinat adenoviruses. J. Virol. 69:1995;2004-2015.
46. Yang Y., Su Q., Grewal I. S., Schilz R., Flavell R. A., Wilson J. M. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J. Virol. 70:1996;6370-6377.